{
    "title": "Regeneron profit beats, expects early results from COVID-19 trials in September",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8595769/Regeneron-profit-beats-Dupixent-strength.html",
    "date": "2020-08-05",
    "keywords": [
        "drug",
        "covid19",
        "treatment",
        "eylea",
        "wednesday",
        "dupixent",
        "antibody",
        "month",
        "regeneron",
        "coronavirus",
        "company",
        "weakness",
        "revenue",
        "profit",
        "companys",
        "bell",
        "week",
        "combination",
        "regncov2",
        "disease",
        "rhesus",
        "latestage",
        "spread",
        "hospital",
        "wet",
        "degeneration",
        "wall",
        "street",
        "brokerage",
        "piper",
        "sandler",
        "demand",
        "franchise",
        "segment",
        "credit",
        "analyst",
        "evan",
        "seigerman",
        "jump",
        "collaboration",
        "sanofi",
        "basis",
        "share",
        "quarter",
        "government",
        "development",
        "ebola",
        "reporting",
        "dania",
        "nadeem",
        "manojna",
        "maddipatla",
        "bengaluru",
        "editing",
        "shounak",
        "dasgupta"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}